-

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.

Press release date / time: Tuesday, February 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Wednesday, February 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

Three options for joining the conference call

Register for call back connection

 

Click here:
Connect me

 

Service available 15 minutes before call start

Dial-in by phone

 

 

+1 646 828 8193 (U.S.)

+44 (0)330 165 3655 (UK)

+49 (0)69 2222 25574 (GER)

 

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

 

Conference ID: 5239371

 

Access the audio webcast

 

Click here:

Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1584746&tp_key=0a3819b11c

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2022, QIAGEN employed more than 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
+49 152 018 11457
Email: ir@qiagen.com

Industry:

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN N.V. to release results for Q4 and Full-Year results 2022 and hold webcast
Release Versions
English

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
+49 152 018 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa...

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 2025, exceeding the outlook for an approximately 2% CER decline. QIAGEN’s growth pillars together delivered 5% CER gro...

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis,...
Back to Newsroom